Captixbio is excited to announce Mr Duncan Thomson as our new CEO.
Duncan takes over from former CEO Helen Wray as she continues to work behind the scenes by moving to an advisory position on the board.
Encompassing over 25 years’ experience in life sciences both here in Australia and overseas, including Europe and North America, Duncan’s substantial knowledge in managing animal trials, successful regulatory approvals, product launches, licensing and alliances, sales and marketing will be a huge asset for Captixbio as we look to take the next step in our company trajectory.
“I’m very excited to join Captixbio at a time when there are so many exciting projects underway with our partners and collaborators,” said Duncan. “I can’t wait to continue the success the company has built over the past three years well into the future.”
Former Captixbio CEO and newly appointed Non-Executive Director Helen Wray said having Mr Thomson on board will provide another layer of knowledge to the already stacked leadership team, while opening up some great avenues for the business.
“Duncan’s experience in the big pharma and biotech spaces speaks for itself. We’re pleased to have him as part of our team and can’t wait to continue the journey of Captixbio together into the next half of 2021 and beyond.”